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The etiology of idiopathic pulmonary fibrosis (IPF) remains poorly understood, but some studies
have suggested that cigarette smoking or other occupational or environmental exposures,
diabetes mellitus, or gastroesophageal reflux may play a role. In this study we evaluated the
clinical records of a group of 97 consecutive patients with IPF, and 560 patients suffering 5
different respiratory disorders that were examined as controls: asthma (nZ 111), chronic
obstructive pulmonary disease (nZ 132), squamous cell lung carcinoma (nZ 118), lung adeno-
carcinoma (nZ 101) and patients with otorhinolaryngology problems but without lung disease
(nZ 98). In bivariate analyses male sex, diabetes mellitus and being former cigarette smoker
were associated with IPF. After adjusting by these variables, multivariate analysis revealed
that type 2 diabetes mellitus [11.3% in IPF patients vs 2.9% in controls, ORZ 4.3 (95% CI:
1.9e9.8), p< 0.0001] was an independent risk factor associated to IPF. Our results provide
additional evidence of a putative relationship between DM2 and idiopathic pulmonary fibrosis.
Experimental research is necessary for thorough assessment of the pathogenic mechanisms
involved in this association.
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Idiopathic pulmonary fibrosis (IPF) is a chronic and
progressive scarring lung disease that leads to respiratory
failure and death.1 Although the etiology of IPF is still
unknown, it is considered a complex disorder with a strong
interaction between a genetic background and environ-
mental factors. However, up to now putative genes and
environmental factors that consistently increase the risk of
IPF have not been identified. Smoking presents the most.
306 Ma.C. Garcı´a-Sancho Figueroa et al.striking association with both the sporadic and the familial
forms of IPF.2,3 Likewise, some occupational and environ-
mental exposures, primarily to wood and metal dusts, have
shown to be associated to increased risk of IPF.2 Chronic
viral infection (Epstein-Barr virus) and gastroesophageal
reflux have been also considered as possible risk factors for
this disease.4,5 The incidence of IPF increases with age, and
aging contributes to some lifestyle-related diseases.
Therefore, it is possible that lifestyle-related disorders
such as type 2 diabetes mellitus (DM2) may affect either the
initiation or progression of IPF. Actually, in two studies
performed in different ethnic populations DM2 was found to
be associated with IPF.6,7
In this context, the aim of the present study was to
identify possible risk factors associated to IPF in a Mexican
population. Our results indicated that DM2 is a major
predictor of the disease.
Patients and methods
This was a retrospective case-control, hospital-based study
performed at the National Institute of Respiratory Diseases
(INER), Me´xico. Clinical records of consecutive IPF patients
seen at this institute from 2000 through 2005 were reviewed.
Diagnosis of IPF was made according to established criteria,
and confirmed by lung biopsy in 35% of subjects.8
The control group was integrated by patients who were
seen as outpatients or were hospitalized at the INER due to
selected pulmonary diseases [asthma (nZ 111), chronic
obstructive pulmonary disease (COPD, nZ 132), squamous
cell lung carcinoma (nZ 118), or lung adenocarcinoma
(nZ 100)] and by patients with otorhinolaryngologic (ORL,
nZ 98) problems but without lung disease. Diagnosis of
asthma or COPD were done according to the Global Initia-
tive for Asthma [GINA9] and the Global Initiative for Chronic
Obstructive Lung Disease [GOLD10], respectively. Both
types of lung cancer were confirmed by histopathology.
Regarding ORL patients, individuals included in the analysis
were randomly selected from patients assisting to the ORL
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Data correspond to mean SD or to frequencies (%).were evaluated simultaneously. To confirm specific diag-
noses of cases and controls, the clinical records were
examined twice through standardized methods. Diagnosis
of DM2 was done if the patient had a fasting glucose level
higher than 126 mg/dl (7 mmol/l) in the absence of corti-
costeroids treatment, or the accomplishment of one of the
following criteria: a) the patient knew that he or she had
DM2 diagnosed by a clinician; b) diagnosis of DM2 was done
at INER during the first consult; c) the patient was taking
oral drugs for DM2; d) the patient had used insulin. The
protocol was accepted by the Bioethics and Science
Committee of INER.
Environmental exposures
Information concerning environmental exposures was
obtained from a standardized questionnaire dealing with
risk factors for respiratory diseases. This questionnaire was
systematically applied by the Social Work Department to
any patient admitted to the INER from 1999 onward. The
questionnaire was created and validated by one of the
authors (RPP) and assesses the following risk factors: age,
gender, DM2, smoking habit (current, former, ever); alco-
holism (current, former, ever); occupational exposure to
dusts, smoke or chemicals; location and characteristics of
the home (rural or urban area, construction materials,
number of windows and number of hours they remain open,
number of individuals living with the patient, presence of
children <5 years old, home nearness to a gas station, high-
traffic roads, landfills, dairy or poultry farms, and
manufacturing plants); home exposure to wood smoke,
coal, side-stream tobacco smoke, birds, carpets, dampness
and insecticides.
Statistical analysis
Categorical variables were analyzed through the chi-square
test. Interval variables were expressed as mean and stan-
dard deviation and were compared by the Student’s t-test.
Odds ratios (OR) were calculated through unconditionals (nZ 657).
es (nZ 97) Controls (nZ 560) OR (95%CI)
11.0 62.3 12.2 1.002 (0.9e1.02)
(73.2) 347/560 (62.0) 1.7 (1.03e2.7)
(11.3) 16/560 (2.9) 4.3 (1.95e9.7)
(56.7) 292/560 (52.1) 1.2 (0.8e1.9)
(66.0) 388/560 (69.3) 0.9 (0.5e1.4)
(28.9) 120/560 (21.4) 1.5 (0.9e2.4)
(54.6) 320/560 (57.1) 0.9 (0.6e1.4)
(45.4) 240/560 (42.9) 1.1 (0.7e1.7)
(40.2) 168/560 (30.0) 1.6 (1.006e2.5)
.2) 82/560 (14.6) 0.3 (0.1e0.8)
(37.9) 213/544 (39.2) 0.9 (0.6e1.5)
.4) 129/542 (23.8) 0.3 (0.2e0.7)
(40.2) 221/560 (39.3) 1.03 (0.7e1.6)
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Figure 1 Odds ratios for developing IPF according to
selected variables, as compared with controls.
Table 2 Adjusted odds ratios obtained trough conditional





(95% CI) for IPF
Male sex 0.55 1.7 (1.04e2.9)
Type 2 diabetes 1.46 4.3 (1.9e9.8)
Former smoker 1.15 3.2 (1.2e8.5)
a Additional independent variables evaluated in (and
excluded from) the logistic regression model were ever smoker
and current passive smoker.
Diabetes and idiopathic pulmonary fibrosis 307logistic regression. Variables introduced into regression
models were selected according to a p< 0.20 or its bio-
logical relevance.
Results
Ninety seven patients with IPF and 560 controls with
different lung or ORL diseases were included in the study.
Demographic characteristics are shown in Table 1. As can be
seen in this table, both groups did not differ regarding age,
occupational exposure to dusts, smoke or chemicals, or
alcohol intake. Male gender was slightly more frequent
among IPF patients. Themost striking differencewas related
to DM2 and exposure to tobacco smoke. Thus, a higher
proportion of subjects with DM2 was found among cases
(11.3%) as compared with controls (2.9%, p< 0.0001),
yielding over a four-fold risk of IPF among DM2 subjects. The
increased frequency ofDMwas evenhigher in the subgroup of
IPF patients who had undergone surgical lung biopsy to
confirm diagnosis biopsied: OR 6.8 (2.0e22.6); non-biopsied:
OR 3.6 (1.2e9.6). A more in-deep analysis showed that IPF
patients had such increased risk compared with almost all of
the five subgroups of control patients. Thus, odds ratios (95%
confidence intervals) were 4.6 (1.2e26.3) for asthma, 2.7
(0.9e9.2) for COPD, 3.7 (1.03e16.3) for squamous cell
cancer, 6.3 (1.3e59.3) for lung adenocarcinoma, and 6.2
(1.3e58.7) for ORL control subgroups. Likewise, IPF patients
showed a higher frequency of former smokers (40.2 vs 30.0%,
pZ 0.04), and less current active or passive smokers (5.2 vs
14.6%, pZ 0.01, and 9.4 vs 23.8%, pZ 0.002, respectively).
The increased percentage of current active and passive
smokers in the control group was mainly due to a higher
proportion of smokers amongCOPDand squamous cell cancer
patients (data not shown).
Odds ratios and 95% confidence intervals for household
characteristics are shown in Fig. 1. All variables lacked
statistically significant differences between both groups.
After adjusting by sex, former smoker, current active
and passive smoker, multivariate analysis shown that DM2
was the most important independent predictor associated
to IPF risk [ORZ 4.3 (1.9e9.8) p< 0.0001, Table 2].
Discussion
IPF is the most common idiopathic interstitial pneumonia
and the one with the worst prognosis. Thus, despite
intensive research an effective therapy for this disease
remains elusive. Etiology of IPF is unknown but several
epidemiological observations associate the risk of devel-
oping this disease to an environmental injury to the lungs.
Recognition of these and other risk factors may be crucial
to prevent the development of the disease.
In this study, we approached the question about risk
factors through a case-control study using a questionnaire
administered by social workers to collect information
regarding household characteristics, environmental expo-
sures and other pertinent data.
Our results showed that DM2 was significantly associated
to a higher risk for IPF. Thus, after adjusting for con-
founding factors, there was a more than 4-fold increase in
odds for developing IPF among diabetics. Similar resultshave been reported in two previous studies involving
different ethnic populations.6,7 In one of them, a case-
control study performed in the setting of a longitudinal
primary-care database in the United Kingdom showed that
IPF was significantly associated to diabetes-related condi-
tions, being insulin use the factor with the strongest asso-
ciation.7 Interestingly, in this study no association with the
smoking status was found. Similar results were reported in
a Japanese population, where 64 IPF patients were
compared with 184 control subjects without evidence of
lung disease in their chest radiographs.6 In this case-control
study, the prevalence of DM2 was 3-fold higher in the IPF
group. On the contrary, in a more recent study also per-
formed in Japanese population, IPF patients were
Co
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bacterial pneumonia and outpatients with common cold),
concluding that diabetes was no associated to IPF.11
Studies regarding fibrosis in organs other than the lungs
have also found some association with DM2. For example,
history of diabetes was an independent clinical parameter
associated with advanced fibrosis in patients with chronic
hepatitis C.12 Likewise, the incidence of chronic nonalco-
holic liver disease is significantly higher among patients
with diabetes.13 Furthermore, fibrosis is a frequent patho-
logical reaction in tissues affected by diabetic complica-
tions.14 The pathogenic mechanisms implicated in the
association of diabetes and IPF are presently unknown. High
extracellular and intracellular glucose environment may
activate several pathways related to the production of
cytokines, growth factors, and reactive oxidative species,
which can mediate tissue damage and fibrosis in diabetes.
For example, it has been recently shown that connective
tissue growth factor (CTGF) mediates high glucose and
palmitate induced cardiac myocyte hypertrophy and
dysfunction as well as cardiac fibrosis.15 Interestingly, CTGF
has been recently implicated in the epithelial to mesen-
chymal transition (EMT) of renal tubular epithelial cells
which contributes to the renal fibrosis associated with
diabetic nephropathy.16 EMT is also involved in the expan-
sion of the population of fibroblasts/myofibroblasts in IPF
lungs, although a putative relationship with diabetes has
not been evaluated.17,18 Many other factors play roles in
the pathogenesis of diabetic nephropathy and fibrosis; for
instance, both TGF-b1 and angiotensin II are important
factors to promote the development of renal fibrosis.19
These mediators are also implicated in the pathogenesis of
IPF.20 Furthermore, elevated circulating levels of TGF-b1
may be part of the molecular link between diabetes, and
diseases resulting in organ fibrosis.21
A high prevalence of current or former smokers has been
reported in several series of IPF patients. In a recent meta-
analysis of observational studies examining environmental
and occupational risk factors for IPF, a significant increased
risk for IPF was associated with cigarette smoking.2 In
a large study including 248 cases and 491 control subjects
identified through random-digit dialing, matched by
gender, age and geographic region, a history of ever or
former smoking was associated with increased risk for the
development of IPF.22 Also, evidence suggestive of an
interaction between smoking and agricultural work has
been found.23 However, some contradictory results have
also been reported, which may be partially related to the
utilization of different control groups (i.e., community or
hospitalized controls), small size samples, and uncertainty
of IPF diagnosis since several studies were performed
before the 2000 year when a consensus diagnosis was
published.2,8,22e24
In our study, we found by bivariate and multivariate
analyses a higher proportion of former smokers in the IPF
group. Interestingly however, an increased proportion of
current smokers was found among control patients that is
explained by the high proportion of them in the COPD and
squamous lung cancer subgroups, two diseases strongly
associated to cigarette smoking.
Exposure to biomass smoke was explored because in
developing countries many households in rural areas or inthe periphery of urban areas depend on biomass for cooking
and heating, and this exposure has been associated to
pulmonary fibrosis in one study and some case reports.24,25
However, no association was found, probably because the
high prevalence of exposure in all subgroups of patients
with chronic respiratory disorders. Likewise, none of the
other studied factors showed statistical significance.
This study has several potential weaknesses that restrict
the power of the results. Among them, the retrospective
collection of data and the relatively small sample size limit
the statistical power to detect other putative associations
between exposures and the disease. This is primarily due to
the low prevalence of IPF that makes the number of
patients available for conducting etiologic studies usually
small. The main strength of our study is the validity of the
diagnosis of IPF (ATS consensus) and of the other diseases
that constituted the control group.
In summary, our findings indicate that DM2 might
constitute a risk factor for developing IPF in Mexican pop-
ulation. The pathogenic mechanisms implicated in this
association remain to be elucidated. Further studies are
needed to confirm the putative relationship of IPF with
smoking.
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